TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02385461
Drug: Low Molecular Weight Heparins (LMWHs)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03684655
Drug: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
Study: NCT01116050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 tablets in opque introducer
Study: NCT02842931
Drug: R-DA-EPOCH-21
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
Study: NCT02842931
Drug: R-DA-EPOCH-21 + auto-SCT
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
Study: NCT02842931
Drug: R-mNHL-BFM-90
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
Study: NCT02842931
Drug: R-mNHL-BFM-90 + auto-SCT
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
Study: NCT02265913
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04331080
Drug: Granexin® gel 100 μM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Study: NCT04331080
Drug: Granexin® gel 200 μM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Study: NCT04331080
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Study: NCT00862251
Drug: ezetimibe (+) simvastatin
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
Study: NCT00862251
Drug: simvastatin 40 mg or atorvastatin 20 mg
Normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
Study: NCT00862251
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 10 mg tablets, taken once daily for six weeks.
Study: NCT00862251
Drug: atorvastatin 10 mg or simvastatin 20 mg
Normalized name: simvastatin 10 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
Study: NCT01262898
Drug: GSK962040 (5 mg tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tablet
Study: NCT01262898
Drug: GSK962040 (25 mg tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tablet
Study: NCT01262898
Drug: GSK962040 (125 mg tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg tablet
Study: NCT01262898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet
Study: NCT00046722
Drug: Smoked Marijuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03304522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matched to VX-150 for 6 weeks.
Study: NCT02351115
Drug: A=Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02351115
Drug: E=Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01818544
Drug: BAY85-8501
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
Study: NCT01818544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
Study: NCT02717091
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01645709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03532789
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: One patch without medicine should be applied to the skin every other day within two weeks
Study: NCT04249882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched to active medication
Study: NCT02176486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib placebo-matching capsules.
Study: NCT01872013
Drug: ASP7991
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01872013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03233035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
Study: NCT01392833
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
Study: NCT01814657
Drug: Sterile Normal Saline%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
Study: NCT01884298
Drug: remifentanil(Ultiva)
Normalized name: remifentanil Injection [Ultiva]
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
Study: NCT03701659
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrine therapy for advanced prostate cancer.
Study: NCT01470027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: effervescent tablets
Study: NCT04558697
Drug: Hyperici extractum oleosum vagitories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperici extractum oleosum vagitories will be administered once daily for 5 days
Study: NCT04558697
Drug: Vagitories - Probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagitories - Probiotic will be administered once daily for 5 days
Study: NCT01755169
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00098787
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00098787
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00864734
Drug: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
Study: NCT00643149
Drug: azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
Study: NCT00201539
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
Study: NCT02243787
Drug: COVA322
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02388321
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Study: NCT00764725
Drug: conventional DMARD combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
Study: NCT01636557
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Study: NCT01311778
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
Study: NCT03830671
Drug: 18-month regimen containing 6 anti-TB drugs
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months
Study: NCT00508729
Drug: Qingyi granules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01244737
Drug: [18F] FLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
Study: NCT01274221
Drug: SPD489
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
Study: NCT01225354
Drug: Calcium hydroxylapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
Study: NCT03860506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01901887
Drug: Study Juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
Study: NCT01901887
Drug: Placebo Juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
Study: NCT00743795
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral BID
Study: NCT01995890
Drug: nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00384579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00049348
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01339650
Drug: ABT-767
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-767 once or twice daily for a 28 day cycle
Study: NCT02565641
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally at 830 mg/m\^2 BID (equivalent to a total daily dose of 1660 mg/m\^2) as intermittent treatment (given days 1 to 21 q4w).
Study: NCT01494285
Drug: ARK-E021 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically applied once daily at bedtime
Study: NCT01494285
Drug: ARK-E021 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically applied once daily at bedtime
Study: NCT01494285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically applied once daily at bedtime
Study: NCT01117376
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin 250 mg intravenous Q6h for 4 doses
Study: NCT00613626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo oral daily
Study: NCT00613626
Drug: ZD6474
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD6474 100mg oral daily to be continued for the duration of the study.
Study: NCT02624648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will receive a capsule of Placebo twice a day for 120 days
Study: NCT00324103
Drug: Structured Treatment Interruptions
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01097902
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg oral one time only
Study: NCT01097902
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet oral one time only
Study: NCT00213239
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
Study: NCT00213239
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
Study: NCT04472689
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation
Study: NCT00877838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules resembling the ones containing the active substance
Study: NCT00866437
Drug: Skin test panel
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Study: NCT00866437
Drug: Skin test panel
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1 mmol/L~3. Estrone 3 mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Study: NCT03959189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT02101008
Drug: disulfiram and chelated zinc
Normalized name: zinc, chelated
DrugBank: Zinc (DB01593)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00470821
Drug: Oral melatonin 3mg BID
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
Study: NCT00470821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
Study: NCT02013323
Drug: Scaling and root planing, and Septilin for 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
Study: NCT02013323
Drug: Scaling and root planing, and Placebo drug for 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
Study: NCT00001303
Drug: Reference Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001303
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04321343
Drug: PXL065
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXL065 oral tablet
Study: NCT04321343
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT00590161
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tid
Study: NCT03981601
Drug: Lovastatin 40 MG
Normalized name: lovastatin 40 MG
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
Study: NCT01261403
Drug: Vehicle Controlled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7
Study: NCT01653301
Drug: XELAC RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost).
Study: NCT02332486
Drug: Qingxuan Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
Study: NCT00256789
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01653301
Drug: XELOX RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~* Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost).
Study: NCT01960010
Drug: MIM-D3 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% MIM-D3 dosed BID
Study: NCT01960010
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle dosed BID
Study: NCT02871479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo cream containing the same components as the vehicle for the active intervention arm
Study: NCT02006576
Drug: 600 mg ibuprofen three times daily for 48 weeks
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01151137
Drug: Placebo (for Dronedarone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)
Study: NCT01097044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
Study: NCT00785577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks
Study: NCT00785577
Drug: LY545694 49 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks.
Study: NCT00785577
Drug: LY545694 105 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks
Study: NCT00025038
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01212445
Drug: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
Study: NCT03542994
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01381081
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single betamethasone and bupivacaine intra-articular injection
Study: NCT03551522
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo Capsule
Study: NCT00030082
Drug: isolated perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00601978
Drug: carbidopa/levodopa
Normalized name: CARBIDOPA/LEVODOPA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00601978
Drug: Carbidopa/Levodopa/Entacapone
Normalized name: carbidopa/levodopa/entacapone 25 mg-100 mg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02451956
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
Study: NCT03217162
Drug: surfactant combined with mechanical ventilation (MV)
Normalized name: surfactant protein-D homotrimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
Study: NCT03887936
Drug: Testosterone gel 1.62%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone gel 1.62%, apply 2 pumps to upper arm and shoulder.
Study: NCT03887936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo gel, apply 2 pumps to upper arm and shoulder
Study: NCT02427165
Drug: RPL554
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dual PDE3 and PDE4 inhibitor